View Older Stories View More Recent Stories

Jan 23, 2020 07:00AM Cadent Therapeutics Announces FDA Acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)
Jan 13, 2020 08:00AM Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
Jan 10, 2020 07:10AM Generation Bio to Present at 38th Annual J.P. Morgan Healthcare Conference
Jan 10, 2020 07:00AM Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
Jan 8, 2020 06:03AM Karl Naegler joins Wellington Partners as Managing Partner
Jan 2, 2020 05:19PM Form 4 Akero Therapeutics, Inc. For: Dec 31 Filed by: Atlas Venture Fund XI, L.P.
Dec 19, 2019 05:35PM Form 4 Akero Therapeutics, Inc. For: Dec 17 Filed by: Atlas Venture Fund XI, L.P.
Dec 17, 2019 08:30AM Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair
Dec 17, 2019 06:00AM Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders
Dec 10, 2019 05:30PM Cadent Therapeutics Announces Poster Presentation at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Dec 3, 2019 07:00AM Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth
Dec 2, 2019 07:00AM Cadent Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference
Dec 2, 2019 06:30AM IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer
Nov 25, 2019 05:17PM Form SC 13D Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Nov 20, 2019 05:50PM Form 3 Replimune Group, Inc. For: Nov 18 Filed by: Atlas Venture Associates Opportunity I, L.P.
Nov 20, 2019 01:41PM New Research Demonstrates Second Direct Link Between Inflammasome Activation and Alzheimer's Disease
Nov 20, 2019 07:00AM Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer
Nov 14, 2019 07:00AM Cadent Therapeutics to Present at Upcoming Investor Conferences
Nov 12, 2019 11:22AM Form 13F-HR Atlas Venture Associates For: Sep 30
Nov 12, 2019 11:21AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 12, 2019 11:21AM Form 13F-NT ATLAS VENTURE FUND VI For: Sep 30
Nov 12, 2019 11:20AM Form 13F-HR Atlas Venture Advisors, For: Sep 30
Nov 12, 2019 11:20AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 11, 2019 08:30AM Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965
Nov 7, 2019 05:00AM Arkuda Therapeutics Closes $44M Series A Financing to Advance Novel Medicines Targeting Progranulin and Lysosomal Biology to Treat Neurodegenerative Diseases
Oct 29, 2019 08:00AM Generation Bio Welcomes Steven Dowdy, Ph.D., to its Scientific Advisory Board
Oct 29, 2019 07:00AM CAMP4 Therapeutics Expands Board of Directors With Appointment of Steven Holtzman as Chair and Dr. Paula Ragan as Director
Oct 29, 2019 07:00AM Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Oct 22, 2019 12:00PM Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo
Oct 21, 2019 08:00AM Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
Oct 17, 2019 08:00AM Cadent Therapeutics Appoints Christopher Kenney, M.D. as Chief Medical Officer and Provides Clinical Update
Oct 14, 2019 07:00AM Cadent Therapeutics to Present at the 5th Annual BMO Private Company Showcase
Oct 7, 2019 06:00AM Korro Bio Launched to Advance Groundbreaking New Approach to Nucleic Acid Editing
Oct 1, 2019 06:30AM Dyne Therapeutics Announces Appointment of Joshua Brumm as President and Chief Executive Officer
Sep 11, 2019 08:00AM Disarm Therapeutics Presents Data at ECTRIMS 2019 Supporting SARM1 as a Novel Therapeutic Target for Multiple Sclerosis
Sep 5, 2019 07:00AM IFM Therapeutics Announces Collaboration and Exclusive Option Agreement for cGAS/STING-Focused Subsidiary, IFM Due
Sep 4, 2019 08:00AM Disarm Therapeutics Announces First Subject Enrolled in EPIPHANY Natural History Study of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Aug 28, 2019 07:00AM Cadent Therapeutics to Present at Upcoming Investor Conferences
Aug 23, 2019 08:00AM Disarm Therapeutics Announces Science Publications Elucidating Structure and Function of SARM1
Aug 21, 2019 07:00AM Cadent Therapeutics Appoints John McBride as Chief Financial Officer and Expands its Leadership Team
Aug 19, 2019 08:00AM Dyne Therapeutics Expands Board of Directors with Appointment of Lawrence Klein
Aug 6, 2019 02:12PM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Aug 6, 2019 02:11PM Form 13F-NT ATLAS VENTURE FUND VI For: Jun 30
Aug 6, 2019 02:11PM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 6, 2019 02:10PM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 6, 2019 02:10PM Form 13F-HR Atlas Venture Associates For: Jun 30
Jul 30, 2019 05:26PM Form SC 13D AVROBIO, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 29, 2019 09:13PM Form 4/A AVROBIO, Inc. For: Jul 19 Filed by: Atlas Venture Fund X, L.P.
Jul 29, 2019 09:12PM Form 3 AVROBIO, Inc. For: Jul 19 Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 25, 2019 07:30AM Obsidian Therapeutics Announces Strengthening of Executive Leadership Team
View More Recent Stories View Older Stories